Analysts say these ASX 200 blue chip shares are buys in July

These could be the blue chip shares to strengthen your portfolio with in July.

| More on:
a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're looking for some new portfolio additions in July, then it could be worth looking at the ASX 200 blue-chip shares listed below that have recently been named as buys.

Here's why brokers are positive on these top shares:

Goodman Group (ASX: GMG)

The team at Citi believes that Goodman Group could be an ASX 200 blue chip share to buy.

It is an integrated industrial property company with a world-class portfolio of assets across the globe. It also has a development pipeline filled to the brim with properties that are likely to support its growth for the foreseeable future.

It is partly for this reason that Citi believes Goodman is well-positioned to deliver solid earnings growth for the foreseeable future. It said:

We see potential for GMG to generate consistent high-single to low-double digit earnings growth over the medium term driven by rental upside and longer term development projects, which will add to management and development earnings. The stock currently trades at c. 19x FY24e, below global industrial peers, despite having higher earnings growth and lower leverage. We therefore see upside to the share price and retain Buy.

Citi has a buy rating and a $24.30 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX 200 blue-chip share that could be a buy in July is ResMed.

It is a healthcare company involved in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep-disordered breathing, chronic obstructive pulmonary disease, (COPD), neuromuscular disease, and other chronic diseases.

Goldman Sachs is a fan of the company and sees a lot of value in its shares at current levels. The broker explains:

We continue to see a long-duration runway of HSD organic growth for RMD, and we believe valuations (PE: 31.4x / EV/EBITDA: 22.0x) both c.6% below 5-year averages and growth-adjusted valuation of 2.6x (sector 2.4x) are not demanding in the context of various near/long-dated tailwinds.

Goldman has a buy rating and a $39.60 price target on the company's shares.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

2 women looking at phone
Blue Chip Shares

3 high quality blue chip ASX 200 shares to buy in November

Here are a few blue chip shares that have been rated as buys this month by analysts.

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Blue Chip Shares

2 of the highest-quality blue chip ASX 200 stocks money can buy

Analysts think these blue chips are top buys for investors right now. But why?

Read more »

Three smiling corporate people examine a model of a new building complex.
Blue Chip Shares

This blue chip ASX 200 stock is 'among the highest-quality names' under coverage

Goldman Sachs thinks this blue chip is a top buy.

Read more »

A business woman flexes her muscles overlooking a city scape below.
Blue Chip Shares

Brokers name 2 strong ASX 200 shares to buy now

These shares are among the top picks on the benchmark ASX 200 index according to analysts.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Blue Chip Shares

Up 47% in a year: This blue chip ASX 200 stock can keep rising

Bell Potter is feeling bullish about this stock. But why?

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

Should you buy Coles and Mineral Resources shares this month?

Are these blue chips buys? Let's see what Bell Potter is saying about them.

Read more »

Happy man working on his laptop.
Blue Chip Shares

These big ASX 200 blue chip shares could rise 20% to 50%

Analysts think these blue chips could be cheap at current levels.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Blue Chip Shares

Why this ASX 200 share is one of the 'highest-quality names'

Goldman Sachs is a huge fan of this blue chip. But why?

Read more »